65.00Open65.00Pre Close0 Volume0 Open Interest310.00Strike Price0.00Turnover3674.82%IV0.52%PremiumJan 17, 2025Expiry Date63.73Intrinsic Value100Multiplier-2DDays to Expiry1.27Extrinsic Value100Contract SizeAmericanOptions Type-0.9954Delta0.0006Gamma3.87Leverage Ratio-60.1258Theta0.0000Rho-3.85Eff Leverage0.0001Vega
Alnylam Pharmaceuticals Stock Discussion
Alnylam Highlights New Data From HELIOS-B Study of Vutrisiran for the Treatment of Transthyretin Amyloidosis With Cardiomyopathy at Heart Failure Society of America Annual Scientific Meeting 2024 | ALNY Stock News
ALNY BUY ALERT 🚨 DRUG NEWS MULTIPLE PRICE TARGET RAISES
No comment yet